With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.780753-89-1,1-(4-Fluorophenyl)piperazin-2-one,as a common compound, the synthetic route is as follows.
780753-89-1, Example 13 4-[(2,3-Dichlorophenyl)carbonyl]-1 -(4-fluorophenyl)-2-piperazinone (E13); 1-(4-Fluorophenyl)-2-piperazinone (150mg, 0.77 mmol, prepared as described above for Example 12) and lambda/-ethyl-lambda/-(1-methylethyl)-2-propanamine (0.20 ml, 1.16 mmol) were added together in dichloromethane (4 ml) at O0C. Subsequently 2,3- dichlorobenzoyl chloride (178 mg, 0.85 mmol) was added portionwise. The mixture was left under argon and in an icebath and allowed to return to room temperature whilst being stirred constantly overnight. Dichloromethane and aqueous 3N citric acid were then added and the mixture was extracted into dichloromethane (x2). The dichloromethane layers were combined and washed sequentially with water (x1 ), saturated aqueous sodium hydrogen carbonate (x1 ), water (x1 ), and brine (x1 ), and then dried over magnesium sulphate. The solvent was evaporated in vacuo to give 4-[(2,3-dichlorophenyl)carbonyl]-1-(4-fluorophenyl)-2-piperazinone (224 mg) as a white solid. LC/MS [M+H]+ = 367, retention time = 2.62 minutes.
As the paragraph descriping shows that 780753-89-1 is playing an increasingly important role.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2009/53459; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics